Serum proteins as tumour markers for breast cancer. by Mattison, P. et al.
Br. J. Cancer (1981) 43, 542
Short Communication
SERUM PROTEINS AS TUMOUR MARKERS FOR BREAST CANCER
P. MATTISON*, D. H. COVE*, L. WALSH*, A. HOWELL*t,
B. McCONKEY* AND J. M. MORRISON:
From *The Dudley Road Hospital, Birmingham B18 7QH, tThe Department of Medicine,
University of Birmingham, B15 2TH and ISelly Oak Hospital, Birnmingham B29 6JD
Received 15 October 1980
MOST PATIENTS undergoing mastectomy
for what appears to be local breast cancer
subsequently die from disseminated
disease, suggesting that metastases are
present at the time of initial surgery.
Systemic therapy given as an adjuvant to
surgery may be beneficial (Bonnadonna
et al., 1976) but patients can only be
selected for treatment by imprecise prog-
nostic factors, and responses can only be
judged by changes in disease-free interval
and survival. A direct estimate of tumour
load would be ofmajor clinical importance
in identifying patients with micrometa-
stases and monitoring adjuvant therapy.
Tumour products are precise markers for
some cancers (Bagshawe, 1974; Hobbs,
1971; Melvin et al., 1972) but we have
studied several products of breast neo-
plasia and found them to be released in
insufficient quantities tobesensitive guides
of tumour burden (Cove et al., 1979a,b;
Woods et al., 1979).
Inflammatory disease can be monitored
by serial estimations of serum proteins
(McConkey et al., 1972). Raised levels are
detectable in patients with colonic (Milford
Ward et al., 1977), bronchial (Bradwell,
1979) and breast neoplasia (Coombes et
al., 1977) and a rise in acute-phase protein
precedes clinical evidence of recurrent
bronchial cancer by up to 10 months
(Bradwell, 1]979). We have studied 5
serum proteins in patients who were par-
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ticipating in a trial of adjuvant chemo-
therapy and who developed recurrent
breast cancer.
All patients entered into the chemo-
therapy trial were women under the age of
65 who had no serious intercurrent illness,
with operable breast cancer and no
clinical or radiological evidence of meta-
stasis at the time of mastectomy. Patients
were randomized into treatment or un-
treated control groups, and followed at
3-monthly intervals by clinical examina-
tion and biochemical profile, and at 6-
monthly intervals by skeletal survey,
chest X-ray and bone scan. Recurrence of
tumour was diagnosed histologically or
radiologically. Serum for tumour-marker
studies was taken preoperatively and at
the time of recurrence. Serial samples at
3-monthly intervals after mastectomy
were obtained from patients attending 4
of the 8 follow-up centres. Serum was
frozen within 4 h of venesection and
stored at - 40°C for 3-24 months.
The proteins were estimated in sera
collected from 50 patients when the re-
current tumour was identified. Of the 35
patients with one or more elevated protein
concentrations, stored serum samples
taken at 3-monthly intervals from the
time of mastectomy were available for 21.
In the present study, serum protein con-
centrations at recurrence are compared
with levels 3 months earlier and 3 months
CorIespondence to: I)r D. H. Cove, now at Weymnouitl, and( D)istrict lospital, Weymouttl, Dorset, DT4 7TB.MARKERS FOR BREAST CANCER
TABLE I.-Patix
No. patieIits
Age meani +s.5(.
Initial Stage I
II
Receiving chemotlherapy
DFIt mean + s.d. (months)
median (months)
Site of recurrence
(No. patients)
Scar
Lymplh node
Bone
Liver
Breast
Lung
Other
* Those patieints in wlhom
tions were made.
t Disease-free interval.
ent details
All Subgroups*
50 21
49+9 50+11
8 1
42 20
23 11
11+6 12+5
11
14
17
18
7
4
4
2
5
7
10
1
2
0
1
serial protein estima-
after mastectomy in these 21 patients.
The clinical features of the patients
studied are summarized in Table I.
The serum proteins were estimated by
the Mancini radial immunodiffusion
method (Mancini et al., 1965). The antisera
and standard proteins were obtained from
Seward Laboratories (C-reactive protein
(CRP)) and Hoechst Pharmaceuticals (cil-
antitrypsin, haptoglobin, orosomucoid and
prealbumin) and the upper limits of
normal were taken as 10 mg/l, 4 g/l, 2-6
g/l, 1-4 g/l and 0'4 g/l respectively
(Behring, 1979). The lower limit of normal
for prealbumin was taken as 0-1 g/l. The
inter- and intra-assay coefficients ofvaria-
tion were less than 500.
The mean protein concentrations and
the number of patients with raised levels
are reported (Table II). Changes in protein
concentrations up to recurrence are sum-
marized as l of 4 categories for each pro-
tein: (a) variation within the normal
range; (b) a rise of > 25% of the initial
concentration; (c) a fall of > 25% of the
initial concentration; (d) a change of
< 25%. In Categories (b), (c) and (d) the
protein concentration on one or both
occasions was greater than the upper limit
ofnormal.
At the time ofrecurrence 35/50 patients
had raised concentrations of one or more
proteins. Alpha1-antitrypsin and hapto-
globin were each raised in 42 0 ofpatients,
CRP in 22% and orosomucoid in 14%, but
high levels (> 2 x normal) were uncom-
mon (Table II). Pre-albumin concentra-
tions were normal in all patients. Protein
abnormalities did not appear to be asso-
ciated with the site of recurrence or treat-
ment with chemotherapy (data not given).
In 21 patients, all of whom had raised
levels of one or more proteins at the time
of recurrence, the concentrations of CRP,
oal-antitrypsin, haptoglobin and oroso-
mucoid were compared from 3 months
after mastectomy to recurrence, and from
3 months before recurrence to recurrence
(Table III). There was no significant rise
in any of the mean protein concentrations
despite clinical progression of disease. In
patients with protein levels above the
normal range there was no consistent
change during follow-up. For example,
from 3 months postoperatively to the
time of recurrence, although oal-anti-
trypsin levels rose in 9 patients they fell
in 2, remained static above the normal
range in 8 and were within the normal
range in 2 (Table III). Similar variability
was found for all 4 proteins and for both
follow-up periods, and could not be
accounted for by the site of recurrence or
treatment with chemotherapy.
In some patients serial 3-monthly pro-
TABLE II. Protein concentrations in 50 patients at the time of clinical recurrence
a1-Anti- Hapto- Oroso- Pre-
CRP trypsin globin mucoid albumin
Protein (mg/l) (g/l) (g/l) (g/l) (g/l)
felan±S.(l. * 4-2+ 1-4 2-7+1I-1 1-2+ :3 0-2+0-06
No. > nollllal 11 21 21 7 0
No. > 2 x noi-inal 1 1 0
* lF're(quenitly unidetectable.
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TABLE III.-The concentration of each protein in 21 patients at the 3 follow-up periods
CRP
3 months after operation
3 months before recurrence
( -antitrypsin
3 months after operation
3 months before recurrence
At recurrence
Haptoglobin
3 months after operation
3 months before recuirrenrce
At recurrence
Orosomucoid
3 months after operation
3 months before recurrence
At iecurrence
* Fiequently undetectable.
Concentration ,
ofprotein
(g/l)
Mean + s.d.
*
No. of patients showing change (huring
follow-up
>Upper limit of normal <Upper ~~
A ___" limit of
Rise Fall No clhange normal
3 2 0 16
4 1 0 16
4-2+ 11
4-2 + 1-2
4-9+ 16
2-8 + 1-3
2-9 + 1-3
2-9 + 1-1
1-1 +0(35
1-1 + 0 30
1-2+0-26
tein levels were consistently above the
normal range, whilst in others there were
considerable fluctuations unrelated to
clinical recurrence of tumour or to chemo-
therapy.
No single tumour marker has yet been
found which can effectively monitor the
progress of disease in patients with breast
cancer. Eighty to 90%0 (Cove et al., 1979b;
Coombes et al., 1977; Franchimont et al.,
1976) of patients with advanced disease
have raised serum levels of one or more
tumour-associated substances, suggesting
that a combination of parameters might
be a more sensitive guide of tumour load.
In a previous report we found haptoglobin
concentrations were frequently (40%0) raised in patients with advanced breast
cancer, but usually within the normal
range in those with local disease (Cove et
al., 1979b). Coombes et al. (1977) reported
raised levels of CRP, haptoglobin, oroso-
mucoid and al-antitrypsin in 87%, 38%,
75%0 and 38% respectively of 17 patients
with advanced breast cancer. Pettingale
et al. (1977) found only one (32-glyco-
protein) of 10 plasma proteins to be raised
in patients with local breast cancer, com-
paredc with patients who had benign breast
disease. Patients were followed up for a
9 2 8 2
7 2 9 :3
4 4 7 6
3 1 9 8
2 1 2 16
1 1 3 16
year, but there were too few patients with
tumour recurrence to determine whether
protein measurements were of any value
in predicting clinical recurrence.
Patients in the present study were
highly selected, in that they had to fulfil
the criteria for entry into an adjuvant
chemotherapy trial and they had all de-
veloped recurrent tumour. The patients
were followed up regularly, thus allowing
a potential tumour marker to be evaluated
by comparison with the best available
method offollow-up. There are few reports
of longitudinal studies of tumour markers
in breast cancer, and only one (Coombes
et al., 1980) in patients followed from
mastectomy to the time of recurrence. An
effective tumour marker at this stage
would be ofparticular value in monitoring
adjuvant chemotherapy.
The upper limits ofnormal for the serum
proteins are closely similar to those of
other published series (Fischer et al., 1976;
Koj, 1974; Bastable et al., 1979). Precise
definition of the normal ranges is limited
by the numerous phenotypes for al-anti-
trypsin and haptoglobin. The present data
tend to confirm that one or more of the
serum proteins are frequently above the
normal ranges in patients with recurrent
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breast cancer. The main aim ofthis study,
however, was not to define the prevalence
ofprotein abnormalities, but to determine
whether protein levels changed appropri-
ately with tumourgrowth during follow-up
and could be ofvalue as tumour markers to
predict recurrence. During follow-up no
overall rise in the concentration of any
protein was found, despite clinical or
radiological appearance of tumour; nor
did we find falls in pre-albumin levels,
reported to give information comple-
mentary to CRP in other diseases (Buckell
et al., 1979). Levels above the normal
range did not rise consistently either from
3 months after operation or from 3
months before recurrence up to the time
ofrecurrence, suggesting that factors other
than tumour load are also important in
determining the concentrations of these
proteins. Unless these factors can be
defined and allowed for, our results leave
little doubt that estimation of these 5
serum proteins has no place in the manage-
ment of patients during follow-up after
mastectomy.
We thank the surgeons participating in the West
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